Thursday, October 22, 2026
RSS

Markets & Money

Visa’s Reported Fireblocks Talks Point to a Bigger Crypto Infrastructure Bet

Visa’s reported talks to acquire Fireblocks for about $2.5 billion could signal a deeper push into institutional blockchain settlement.

October 22, 2026
Pharmaceutical
Pharmaceutical
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.


Tech

Visa’s Reported Fireblocks Talks Show Payments Giant Pushing Deeper Into Crypto Infrastructure

Visa’s reported $2.5 billion Fireblocks talks could deepen its role in blockchain and stablecoin inf…

Oct 22, 2026
Pharmaceutical

AbbVie’s INTREPID Data Strengthens the Case for Dermatology Pipeline Diversification

AbbVie’s Phase 3 INTREPID results show stronger hidradenitis suppurativa responses than the comparat…

Oct 22, 2026
Pharmaceutical

Biohaven Stock Jumps as FDA Accepts Troriluzole Resubmission and Ono Deal Adds Validation

Biohaven’s $BHVN shares jumped 25% after FDA acceptance of its troriluzole resubmission, while an On…

Oct 22, 2026
Pharmaceutical

Cencora’s $2.4 Billion American Oncology Network Deal Pushes Deeper Into Cancer Care

Cencora’s $2.4 billion acquisition of American Oncology Network marks a strategic move from drug dis…

Oct 21, 2026
Pharmaceutical

Unicycive Stock Gains 6.8% After FDA Accepts OLC Resubmission

Unicycive shares rose 6.8% premarket after the FDA accepted its OLC resubmission, creating a regulat…

Oct 21, 2026
Pharmaceutical

BioCryst’s New Orladeyo Formulation Expands Rare-Disease Growth Opportunity

FDA approval of a new Orladeyo oral pellet formulation gives BioCryst a fresh catalyst that could br…

Oct 21, 2026
Pharmaceutical

Jemperli’s Accelerated FDA Approval Could Expand AnaptysBio’s Royalty Opportunity

Jemperli’s expanded FDA approval could strengthen AnaptysBio’s royalty opportunity while limiting it…

Oct 21, 2026
Pharmaceutical

Alcon’s Neurotech Acquisition Deepens Its Push Into Ophthalmic Pharmaceuticals

Alcon’s acquisition of Neurotech Pharmaceuticals could broaden its ophthalmic drug pipeline and expa…

Oct 21, 2026
Pharmaceutical

Cencora’s $2.4 Billion Oncology Acquisition Tests the Case for Vertical Integration

Cencora’s $2.4 billion American Oncology Network deal expands its role from drug distribution into o…

Oct 21, 2026